PHI and BioSpherix sign co-marketing agreement
Phase Holographic Imaging (PHI) and BioSpherix recently signed a collaboration agreement aiming to co-market the companies’ complementary product lines. BioSpherix, NY USA, manufactures and markets advanced cell incubators.
Over 90 % of the drugs tested in humans never reach the market. The high failure rate is a result of that the initial laboratory test gives little or no information of how patients will respond to a new drug. Together, BioSpherix’s and PHI’s products create a novel and powerful concept, allowing researchers to achieve more physiologically relevant and accurate laboratory tests by making it possible to analyze the undisturbed kinetic behavior of cells in a controlled incubator environment.
Cell-based pharmaceutical research in a controlled incubator environment (left) vs. conventional cell-based research in an uncontrolled environment (right).
“We are excited about collaborating with PHI. The combination of our Cytocentric technology with PHI’s HoloMonitor technology provides the ability to monitor cells label-free in full-time physiologically relevant oxygen conditions.* This opens the way to more physiologically relevant results for biomedical sciences”, Alicia D. Henn, PhD MBA, Chief Scientific Officer, BioSpherix.
*Human cells live naturally in an oxygen deprived environment. Conventional experiments are conducted at atmospheric and thus unnaturally high oxygen levels. This results in “oxygen high” cells, as the oxygen concentration is not controlled.
“The general workflow of working with cultured cells has not changed since the 1950s, when scientists were able to keep human cells alive outside the human body for the first time. The combination of our cell friendly technologies takes cell-based biomedical research into a new area, promising to reduce the need for animal testing and the cost of pharmaceutical development”, Peter Egelberg, CEO and founder of PHI.
About BioSpherix
BioSpherix Medical®, located in Parish, NY USA, designs, manufactures, and sells advanced cell incubation for the control and optimization of laboratory cellular environments. Since its founding in 1982, BioSpherix has supplied equipment and systems to academic research, pharmaceutical and biotechnology organizations throughout the world for use in basic cell biology and stem cell research, as well as gene and cellular therapies.
For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: ir@phiab.se
Web: www.phiab.se
This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 18, 2018.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.
